ImmunityBio, Inc. Hits New 52-Week High at $11.00

ImmunityBio, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 11.00 on February 23, 2026. This achievement marks a notable increase from its 52-week low of USD 1.83, reflecting a robust performance over the past year with a remarkable gain of 57.53%. The company's market capitalization stands at USD 8,571 million, indicating its position within the small-cap segment. Despite being loss-making, ImmunityBio has demonstrated impressive financial metrics, including a return on equity of 72.23%. However, it is important to note that the company does not offer a dividend, and its price-to-book ratio is currently at -16.35, suggesting a unique valuation perspective within the industry. As ImmunityBio continues to navigate the competitive landscape of pharmaceuticals and biotechnology, this new high underscores its recent performance trends and market dynamics.